|
Welcome to the 2nd annual Probe Discovery conference and exhibition. This year's event takes place in Washington, capital city of the United States.
The word "probe" is a broad term which can be interpreted to mean any one of a wide variety of agents. These include active chemistries discovered in academic screening labs or in government (MLPCN or the NIH), commercially available probes (i.e. dyes, antibodies, fluorescent proteins), failed drug candidates from Pharma, whole body or cellular imaging agents, specific biomarkers or tool molecules from chemogenomics and/or systems biology efforts. The goal of this conference is to bring all of the various incarnations of probe hunters together to share experience and network to a common purpose.
The conference will be co-located with Ion Channel Targets. Registered delegates will have access to both meetings ensuring a very cost-effective trip.
|
Keynote Speaker |
|
 Hakim Djaballah
Director
Memorial Sloan-Kettering Cancer Centre
|
|
 Douglas Auld
Group Leader, Genomic Assay Technologies
NIH Chemical Genomics Center
National Human Genome Research Institute
|
Agenda Topics
- Failed Drug Candidates as Probes
- Dyes, Antibodies and Fluorescent Proteins
- Whole Body or Cellular Imaging Agents
- Tool Molecules from Chemogenomics
- Innovative Assay Technologies for Probe Discovery
Sponsorship and Exhibition Opportunities
Aaron Woodley, Exhibition Manager
a.woodley@selectbiosciences.com
+44 (0)1787 315129 |
|
Confirmed Speakers
Rathman Chaguturu Director, University of Kansas
Peter Brown Project Manager, Structural Genomics Consortium, University of Toronto
Chris Bologna Associate Professor, University of New Mexico
Sitta Sittampalam Professor, University of Kansas Medical Centre
Michael Olive Vice President, Translational Research,Li-COR Biosciences
Friedrich Kroll Head of Medicinal Chemistry, Caprotec
Dmitriy Minond Senior Scientist, The Scripps Research Institute
Dirk Ullmann Chief Scientific Officer, Proteros Biostructures
Franck Madoux Senior Scientist, Scripps Florida
Terry Riss R&D Director, Promega
Marcie Glicksman Assistant Professor, Brigham and Womens Hospital
Martha Larsen HTS Director, University of Michigan
Jen Pan Group Leader, Broad Institute of Harvard and MIT
Amy Quinn PostDoc Fellow, NIH Genomics Center
Michell Arkin Associate Director, University of California
Christina Ramirez Assay Development Scientist, HTS Core Facility, Memorial Sloan-Kettering Cancer Center
Thomas Chung Project Manager, Conrad Prebys Center for Chemical Genomics, Burnham Institute for Medical Research | |